Optimi Health (OPTH)
NASDAQ:OPTH
OPTH Stock Chart & Stats
$5.67
-$0.18(-3.08%)
―
--
Day’s Range― - ―
52-Week Range$3.00 - $8.82
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$32.79M
Enterprise Value$32.67M
Total Cash (Recent Filing)$106.71K
Total Debt (Recent Filing)$6.57M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 28, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding5,625,897
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue140.89
Enterprise Value/Gross Profit-10.64
Enterprise Value/Ebitda-9.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertical Integration: End-to-end GMP ManufacturingOwning biomass cultivation, extraction, encapsulation and packaging creates durable operational control and quality assurance. This reduces reliance on third parties, supports CDMO services, preserves regulatory compliance, and can sustain long-term margin capture and customer stickiness as demand scales.
Completed GMP Production Run Of 5mg PsilocybinA finished‑drug GMP run validates manufacturing processes and supply readiness for clinical programs in the US and Europe. This reduces execution risk for trials, enables supply agreements, and signals the company can transition from R&D to commercial supply — a structural enabler of sustained revenue.
Australian Regulatory Recognition Expands Addressable MarketFormal regulatory pathways allowing authorized psychiatrists to prescribe psilocybin and MDMA create lasting, institutionally supported demand. For a GMP supplier, this structural policy shift widens market access, legitimizes clinical adoption, and supports multi-year contract opportunities with healthcare providers and trial sponsors.
Bears Say
Negative Gross Profit And Sustained Operating LossesNegative gross profit indicates unit economics currently do not cover direct costs, so revenue growth alone may not produce profitability. Persisting operating losses erode equity, limit reinvestment capacity, and mean the business needs structural cost or price improvements to reach sustainable margins.
Consistent Negative Operating And Free Cash FlowOngoing cash burn forces reliance on external financing and restricts the ability to fund capex, commercial expansion, or R&D internally. Over months this limits strategic flexibility, raises dilution or refinancing risk, and can impede scaling until operating cash flow turns sustainably positive.
Rising Leverage And Weakened Balance SheetMaterially higher debt-to-equity reduces financial flexibility and increases interest and refinancing exposure. Coupled with losses and negative cash flow, elevated leverage heightens solvency risk, constrains opportunistic investments, and may force conservative capital allocation until profitability improves.
OPTH FAQ
What was Optimi Health’s price range in the past 12 months?
Optimi Health lowest stock price was $3.00 and its highest was $8.82 in the past 12 months.
What is Optimi Health’s market cap?
Optimi Health’s market cap is $32.79M.
When is Optimi Health’s upcoming earnings report date?
Optimi Health’s upcoming earnings report date is Aug 28, 2026 which is in 84 days.
How were Optimi Health’s earnings last quarter?
Optimi Health released its earnings results on Jun 01, 2026. The company reported -$0.259 earnings per share for the quarter, the consensus estimate of -$0.259 by $0.
Is Optimi Health overvalued?
According to Wall Street analysts Optimi Health’s price is currently Undervalued.
Does Optimi Health pay dividends?
Optimi Health does not currently pay dividends.
What is Optimi Health’s EPS estimate?
Optimi Health’s EPS estimate is -0.29.
How many shares outstanding does Optimi Health have?
Optimi Health has 5,625,897 shares outstanding.
What happened to Optimi Health’s price movement after its last earnings report?
Optimi Health reported an EPS of -$0.259 in its last earnings report, expectations of -$0.259. Following the earnings report the stock price went up 3.723%.
Which hedge fund is a major shareholder of Optimi Health?
Currently, no hedge funds are holding shares in OPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Optimi Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $41.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.61%
12-Months-Change
Fundamentals
Return on Equity
-57.28%
Trailing 12-Months
Asset Growth
-1.54%
Trailing 12-Months
Company Description
Optimi Health
Optimi Health Corp. develops an integrated functional mushroom brand that focuses on the health and wellness food markets in Canada. The company also focuses on the cultivation, extraction, processing, and distribution of strains of functional mushroom. It offers a range of fungi varieties, which include Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. The company was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.